HFI Connect - Hepatitis

Hepatitis C Drugs Show Patients Benefit Most From Treatment Choice

In an analysis of the past several years of Hepatitis C drug evolution, the costly factors of development, competition, and marketing are examined. Second and third generation Hep C drugs have finally taken hold, recouping multi-billion dollar development costs. With treatment prices in the tens and hundreds of thousands, increased competition in the market raises hopes of lower prices for more effective drugs. Read more science20.com/pfired_but_st...